Barostim implantation with ipsilateral carotid endarterectomy as a one-stage procedure

Hypertension (HTN) remains a significant public health problem with substantial patient morbidity, mortality, and cost to the health care system despite advances in treatment (1). Clinical trials have demonstrated significant and lasting reductions in arterial pressure from baroreflex activation therapy (BAT), which functions by electrical stimulation of the carotid sinus using the Barostim neo â„¢ system in patients with resistant HTN (2, 3). Significant carotid atherosclerosis, however, has been a contraindication for ipsilateral implantation due to increased risk of periprocedural stroke and uncertain antihypertensive efficacy.
Source: Annals of Vascular Surgery - Category: Surgery Authors: Source Type: research